Regeneron Pharmaceuticals, Inc.

What they do

Regeneron invents, develops, manufactures, and commercializes medicines for patients with serious diseases. The company has approximately 50 product candidates in clinical development, most homegrown. Its portfolio includes marketed products such as EYLEA HD, EYLEA, Dupixent, and Libtayo, with collaborations with Sanofi and Bayer. Revenue is generated from product sales and collaboration profit-sharing arrangements.

Revenue drivers

• Dupixent (dupilumab) — Recorded by Sanofi; global net sales increased 38% to $6.0 billion in Q2 2026, a new all-time high. Significant driver of collaboration profit.
• EYLEA HD (aflibercept 8 mg) — U.S. net sales increased 52% to $596 million in Q2 2026, a new all-time high. Used for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
• Libtayo (cemiplimab) — Global net sales increased 30% to $489 million in Q2 2026, a new all-time high.

Recent performance

For Q2 2026, total revenues increased 17% to $4.29 billion versus $3.68 billion in Q2 2025. GAAP net income was $1.30 billion ($12.23 diluted EPS), down 7% from $1.39 billion ($12.81) in Q2 2025. Non-GAAP net income rose 8% to $1.54 billion, with non-GAAP diluted EPS up 11% to $14.29. Full-year 2025 revenue was $14.34 billion and net income was $4.50 billion (diluted EPS $41.48).

Strategy

Management emphasizes continued investment in the pipeline, U.S. manufacturing, and external innovation. They returned nearly $3.0 billion in the first half of 2026 for share repurchases, dividends, capital expenditures, and business development. The company fully repaid the Sanofi Development Balance, which is expected to drive a meaningful step-up in collaboration profits beginning in Q3 2026. Pipeline focus includes regulatory submissions for cemdisiran in generalized myasthenia gravis and continued development of fianlimab and other candidates.

Risks

• Product concentration — Substantial dependence on EYLEA HD, EYLEA, and Dupixent for revenue and collaboration profits.
• Competition and biosimilars — Competing products and biosimilars may be superior or more cost-effective, impacting market share and pricing.
• Regulatory and reimbursement changes — Changes in drug pricing regulations, coverage, and reimbursement from government programs and private payors could affect sales.
• Collaboration dependence — Termination or cancellation of key agreements with Sanofi or Bayer could materially harm operations.

Outlook

Management expects continued double-digit growth in revenues and non-GAAP EPS for Q3 2026, citing strong portfolio momentum and the absence of Sanofi Development Balance repayments. Regulatory approvals for Dupixent (CSU in children) and EYLEA HD dosing extension were received in April 2026. Cemdisiran regulatory submissions were accepted for review by FDA and EMA for generalized myasthenia gravis, with FDA priority review.